Genetics and epigenetics of hepatoblastoma

Pediatric Blood and Cancer

Volumn 59, Issue 5, 2012, Pages 785-792

  Tomlinson, Gail E ^a   Kappler, Roland ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Array CGH; Cytogenetics; Genetic predisposition syndrome

Indexed keywords

ALPHA FETOPROTEIN; APC PROTEIN; AXIN; BETA CATENIN; CALCIUM RELEASE ACTIVATED CALCIUM CHANNEL 1; CASPASE 8; GLYPICAN 3; MICRORNA 100; MICRORNA 214; MICRORNA 221; MICRORNA 222; MICRORNA 29B; PROTEIN P53; RAS PROTEIN; SECRETED FRIZZLED RELATED PROTEIN 1; SUPPRESSOR OF CYTOKINE SIGNALING 1;

BECKWITH WIEDEMANN SYNDROME; CANCER GENETICS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RISK; CHROMOSOME 11P; CHROMOSOME LOSS; CHROMOSOME XP; COLON CANCER; COLON POLYPOSIS; COMPARATIVE GENOMIC HYBRIDIZATION; CONGENITAL DISORDER; CYTOGENETICS; FAMILIAL CANCER; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; GENETIC DISORDER; GERM LINE; GROWTH DISORDER; HEPATOBLASTOMA; HUMAN; LIVER DEVELOPMENT; METHYLATION; PRIORITY JOURNAL; REVIEW; SIMPSON GOLABI BEHMEL SYNDROME; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; TRISOMY 18; TUMOR SUPPRESSOR GENE; WNT SIGNALING PATHWAY;

CHROMOSOMES, HUMAN; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GERM-LINE MUTATION; HEPATOBLASTOMA; HUMANS; LIVER NEOPLASMS; PROGNOSIS; TRANSCRIPTION, GENETIC; TRANSLOCATION, GENETIC;

EID: 84866170410     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24213     Document Type: Review

References (78)

1. Bulterys M, Goodman M, Smith M, et al. Hepatic tumors. In: Ries L, Smith M, Gurney J, editors. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. Bethesda: National Cancer Institute; 1999. pp 91-97.
2. Fraumeni JF, Rosen PJ, Hull EW, et al. Hepatoblastoma in infant sisters. Cancer 1969; 24: 1086-1090.
3. Napoli VM, Campbell WG. Hepatoblastoma in infant sister and brother. Cancer 1077; 39: 2647-2650.
4. Surendran N, Radhakrishna K, Chellam VG. Hepatoblastoma in siblings. J Pediatr Surg 1989; 24: 1169-1171.
5. Kingston JE, Herbert A, Draper GJ, et al. Association between hepatoblastoma and polyposis coli. Arch Dis Child 1983; 58: 959-962.
6. Li FP, Thurber WA, Seddon J, et al. Hepatoblastoma in families with polyposis coli. JAMA 1987; 257: 2475-2477.
7. Garber JE, Li FP, Kingston JE, et al. Hepatoblastoma and familial adenomatous polyposis. J Natl Cancer Inst 1988; 80: 1626-1628.
8. Hughes LJ, Michels VV. Risk of hepatoblastoma in familial adenomatous polyposis. Am J Med Genet 1992; 43: 1023-1025.
9. Hirschman BA, Pollock BH, Tomlinson GE. The spectrum of APC mutations in children with hepatoblastoma from familial adenomatous polyposis kindreds. J Pediatr 2005; 147: 263-266.
10. Sanders RP, Furman WL. Familial adenomatous polyposis in two brothers with hepatoblastoma: Implications for diagnosis and screening. Pediatr Bood Cancer 2006; 47: 851-854.
11. Harvey J, Clark S, Hyer W, et al. Germline APC mutations are not commonly seen in children with sporadic hepatoblastoma. J Pediatr Gastroenterol Nutr 47: 675-677.
12. Ross JA. Hepatoblastoma and birth weight: Too little, too big, or just right? J Pediatr 1997; 130: 516-517.
13. Beckwith J. Macroglossia, omphalocele, adrenal cytomegaly, gigantism and hyperplastic visceromegaly. Birth Defects 1969; 5: 188-196.
14. Wiedemann H. Complexe malformatif familial avec hernie ombilicale et macroglossie-"un syndrome nouveau?" J Genet Hum 1964; 13: 223-232.
15. DeBaun MR, Tucker MA. Risk of cancer during the first four years of life in children from the Beckwith-Wiedemann Syndrome Registry. J Pediatr 1998; 132: 398-400.
16. Clericuzio CL, Chen E, McNeil DE, et al. Serum alpha-fetoprotein screening for hepatoblastoma in children with Beckwith-Wiedemann syndrome or isolated hemihyperplasia J Pediatr 2003; 143: 270-272.
17. Bliek J, Gicquel C, Maas S, et al. Epigenotyping as a tool for the prediction of tumor risk and tumor type in patients with Beckwith-Wiedemann syndrome (BWS). J Pediatr 2004; 145: 796-799.
18. Fukuzawa R, Umezawa A, Ochi K, et al. High frequency of inactivation of the imprinted H19 gene in "sporadic" hepatoblastoma. Int J Cancer 1999; 82: 490-497.
19. Ross JA, Rakloff GA, Davies SM. H19 and IFG-2 allele-specific expression in hepatoblastoma. Br J Cancer 2000; 82: 753-756.
20. Buonuomo PS, Ruggiero A, Vasta I, et al. Second case of hepatoblastoma in a young patient with Simpson-Golabi-Behmel syndrome. Pediatr Hematol Oncol 2005; 22: 623-628.
21. Toretsky JA, Zitomersky NL, Eskenazi AE, et al. Glypican-3 expression in Wilms tumor and hepatoblastoma. J Pedatr Hematol Oncol 2001; 23: 496-499.
22. Zynger DL, Gupta A, Luan C, et al. Expression of glypican 3 in hepatoblastoma: An immunohistochemical study of 65 cases. Hum Pathol 2008; 39: 224-230.
23. Kato M, Takita J, Takahashi K, et al. Hepatoblastoma in a patient with Sotos syndrome. J Pediatr 2009; 155: 937-939.
24. Mussa A, Chiesa N, Porta F, et al. The overlap between Sotos and Beckwith-Wiedemann syndromes. J Pediatr 2010; 156: 1035-1036.
25. Dasouki M, Barr M. Trisomy 18 and hepatic neoplasia. Am J Med Genet 1987; 7: 203-205.
26. Mamlok V, Nichols M, Lockhart L, et al. Trisomy 18 and hepatoblastoma. Am J Med Genet 1989; 33: 125-126.
27. Teraguchi M, Nogi S, Ikemoto Y, et al. Multiple hepatoblastomas associated with trisomy 18 in a 3-year-old girl. Pediatr Hematol Oncol 1997; 14: 463-467.
28. Bove K, Soukup S, Ballard E, et al. Hepatoblastoma in a child with trisomy 18: Cytogenetics, liver anomalies and literature review. Pediatr Pathol Lab Med 1996; 16: 253-262.
29. Maruyama K, Ikeda H, Koizumi T. Hepatoblastoma associated with trisomy 18 syndrome: A case report and a review of the literature. Pediatr Int 2001; 43: 302-305.
30. Kitanovski L, Ovcak Z, Jazbec J. Multifocal hepatoblastoma in a 6-month-old girl with trisomy 18: A case report. J Med Case Reports 2009; 23: 8319.
31. Sameshima Y, Tsunematsu Y, Watanabe S, et al. Detection of novel germ-line p53 mutations in diverse cancer-prone families identified by selecting partients with childhood adrenocortical carcinoma. J Natl Cancer Inst 1992; 84: 703-7037.
32. Toguchida J, Yamaguchi T, Dayton S, et al. Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. New Engl J Med 1992; 326: 1301-1308.
33. Chen TC, Hsieh LL, Kuo TT. Absence of p53 gene mutation and infrequent overexpression of p53 protein in hepatoblastoma. J Pathol 1995; 176: 243-247.
34. Pakakasama S, Chen T, Frawley W, et al. Variation in the myeloperoxidase gene and risk of hepatoblastoma. Int J Cancer 2003; 106: 205-207.
35. Pakakasama S, Chen T, Frawley W, et al. Cyclin D1 polymorphism and age of onset of hepatoblastoma. Oncogene 2004; 23: 4789-4792.
36. Soukup SW, Lampkin BL. Trisomy 2 and 20 in two hepatoblastomas. Genes Chromosomes Cancer 1991; 3: 231-234.
37. Tonk VS, Wilson KS, Timmons CF, et al. Trisomy 2, trisomy 20, and del(17p) as sole chromosomal abnormalities in three cases of hepatoblastoma. Genes Chromosomes Cancer 1994; 11: 199-202.
38. Tomlinson GE, Douglass EC, Pollock BH, et al. Cytogenetic analysis of a large series of hepatoblastoma: Numerical aberrations with recurring translocations involving 1q12-21. Genes Chromosomes Cancer 2005; 44: 177-184.
39. Swarts S, Wisecarver J, Bridge JA. Significance of extra copies of chromosome 20 and the long arm of chromosome 2 in hepatoblastoma. Cancer Genet Cytogenet 1996; 91: 65-67.
40. Kumon K, Kobayashi H, Namiki T, et al. Frequent increase of DNA copy number in the 2q24 chromosomal region and its association with a poor clinical outcome in hepatoblastoma: Cytogenetic and comparative genomic hybridization analysis. Jpn J Cancer Res 2001; 92: 854-862.
41. Schneider N, Cooley L, Finegold M, et al. Report of the first recurring chromosome translocation: der(4)t(1;4)(q12;q34). Genes Chromosomes Cancer 1997; 19: 291-294.
42. Hansen K, Bagtas J, Mark H, et al. Undifferentiated small cell hepatoblastoma with a unique chromosomal translocation: A case report. Pediatr Pathol 1992; 12: 457-462.
43. Gunawan B, Schafer KL, Sattler B, et al. Undifferentiated small cell hepatoblastoma with a chromosomal translocation t(22;22)(q11;q13). Histopathology 2002; 40: 485-487.
44. Trobaugh-Lotrario AD, Tomlinson GE, Finegold MJ, et al. Small cell undifferentiated variant of hepatoblastoma: Adverse clinical and molecular features similar to rhabdoid tumors. Pediatr Blood Cancer 2009; 52: 328-334.
45. Oda H, Imai Y, Nakatsuru Y, et al. Somatic mutations of the APC gene in sporadic hepatoblastomas. Cancer Res 1996; 56: 3320-3323.
46. Koch A, Denkhaus D, Albrecht S, et al. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Cancer Res 1999; 59: 269-273.
47. Udatsu Y, Kusafuka T, Kuroda S, et al. High frequency of beta-catenin mutations in hepatoblastoma. Pediatr Surg Int 2001; 17: 508-512.
48. Blaker H, Hofmann WJ, Rieker RJ, et al. Beta-catenin accumulation and mutation of the CTNNB1 gene in hepatoblastoma. Genes Chromosomes Cancer 1999; 25: 399-402.
49. Park WS, Oh RR, Park JY, et al. Nuclear localization of beta-catenin is an important prognostic factor in hepatoblastoma. J Pathol 2001; 193: 483-490.
50. Taniguchi K, Roberts LR, Aderca IN, et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 2002; 21: 4863-4871.
51. Koch A, Weber N, Waha A, et al. Mutations and elevated transcriptional activity of conductin (AXIN2) in hepatoblastomas. J Pathol 2004; 204: 546-554.
52. Hartmann W, Kuchler J, Koch A, et al. Activation of phosphatidylinositol-3'-kinase/AKT signaling is essential in hepatoblastoma survival. Clin Cancer Res 2009; 15: 4538-4545.
53. Arai Y, Honda S, Haruta M, et al. Genome-wide analysis of allelic imbalances reveals 4q deletions as a poor prognostic factor and MDM4 amplification at 1q32.1 in hepatoblastoma. Genes Chromosomes Cancer 2010; 49: 596-609.
54. Zatkova A, Rouillard JM, Hartmann W, et al. Amplification and overexpression of the IGF2 regulator PLAG1 in hepatoblastoma. Genes Chromosomes Cancer 2004; 39: 126-137.
55. Voz ML, Agten NS, Van de Ven WJ, et al. PLAG1, the main translocation target in pleomorphic adenoma of the salivary glands, is a positive regulator of IGF-II. Cancer Res 2000; 60: 106-113.
56. Gray SG, Eriksson T, Ekstrom C, et al. Altered expression of members of the IGF-axis in hepatoblastomas. Br J Cancer 2000; 82: 1561-1567.
57. Hartmann W, Waha A, Koch A, et al. p57(KIP2) is not mutated in hepatoblastoma but shows increased transcriptional activity in a comparative analysis of the three imprinted genes p57(KIP2), IGF2, and H19. Am J Pathol 2000; 157: 1393-1403.
58. Feinberg AP. Genomic imprinting and gene activation in cancer. Nat Genet 1993; 4: 110-113.
59. Cairo S, Armengol C, De Reynies A, et al. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell 2008; 14: 471-484.
60. Lopez-Terrada D, Gunaratne PH, Adesina AM, et al. Histologic subtypes of hepatoblastoma are characterized by differential canonical Wnt and Notch pathway activation in DLK+ precursors. Hum Pathol 2009; 40: 783-794.
61. Luo JH, Ren B, Keryanov S, et al. Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology 2006; 44: 1012-1024.
62. Hubertus J, Lacher M, Rottenkolber M, et al. Altered expression of imprinted genes in Wilms tumors. Oncol Rep 2011; 25: 817-823.
63. Adesina AM, Lopez-Terrada D, Wong KK, et al. Gene expression profiling reveals signatures characterizing histologic subtypes of hepatoblastoma and global deregulation in cell growth and survival pathways. Hum Pathol 2009; 40: 843-853.
64. Ruiz I, Altaba A, Sanchez P, et al. Gli and hedgehog in cancer: Tumours, embryos and stem cells. Nat Rev Cancer 2002; 2: 361-372.
65. Eichenmuller M, Gruner I, Hagl B, et al. Blocking the hedgehog pathway inhibits hepatoblastoma growth. Hepatology 2009; 49: 482-490.
66. Oue T, Yoneda A, Uehara S, et al. Increased expression of the hedgehog signaling pathway in pediatric solid malignancies. J Pediatr Surg 2010; 45: 387-392.
67. Li YC, Deng YH, Guo ZH, et al. Prognostic value of hedgehog signal component expressions in hepatoblastoma patients. Eur J Med Res 2010; 15: 468-474.
68. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer-A mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006; 6: 107-116.
69. Sakamoto LH, Camargo B, Cajaiba M, et al. MT1G hypermethylation: A potential prognostic marker for hepatoblastoma. Pediatr Res 2010; 67: 387-393.
70. Shih YL, Hsieh CB, Lai HC, et al. SFRP1 suppressed hepatoma cells growth through Wnt canonical signaling pathway. Int J Cancer 2007; 121: 1028-1035.
71. Nagai H, Naka T, Terada Y, et al. Hypermethylation associated with inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human hepatoblastomas. J Hum Genet 2003; 48: 65-69.
72. Honda S, Haruta M, Sugawara W, et al. The methylation status of RASSF1A promoter predicts responsiveness to chemotherapy and eventual cure in hepatoblastoma patients. Int J Cancer 2008; 123: 1117-1125.
73. Harada K, Toyooka S, Maitra A, et al. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene 2002; 21: 4345-4349.
74. Sugawara W, Haruta M, Sasaki F, et al. Promoter hypermethylation of the RASSF1A gene predicts the poor outcome of patients with hepatoblastoma. Pediatr Blood Cancer 2007; 49: 240-249.
75. Osada H, Takahashi T. MicroRNAs in biological processes and carcinogenesis. Carcinogenesis 2007; 28: 2-12.
76. Cairo S, Wang Y, de Reynies A, et al. Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer. Proc Natl Acad Sci USA 2010; 107: 20471-20476.
77. Magrelli A, Azzalin G, Salvatore M, et al. Altered microRNA expression patterns in hepatoblastoma patients. Transl Oncol 2009; 2: 157-163.
78. von Frowein J, Pagel P, Kappler R, et al. MicroRNA-492 is processed from the keratin 19 gene and up-regulated in metastatic hepatoblastoma. Hepatology 2011; 53: 833-842.